IPO Trending
CORONAEQ / NSE, BSEListed

Corona Remedies Limited

Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas including women’s healthcare, cardiology, pain management, urology, and multispecialty segments. As of December 2024, its portfolio includes 67 brands covering women’s health, cardio-diabetic care, pain relief, urology, and multispecialty products such as vitamins, minerals, nutrition, gastrointestinal, and respiratory medications. The company has established a strong pan-India presence with 2,598 medical representatives across 22 states, ensuring deep engagement with healthcare professionals and hospitals. It operates two manufacturing facilities in Gujarat, supporting its production and quality-focused growth strategy in the Indian Pharmaceutical Market.

₹1,008 - ₹1,062144.49x sub
Listed Price1470.00
Listing Gain+38.42%
TimelineBookbuilding IPO
Open08 Dec 2025
Close10 Dec 2025
Allotment11 Dec 2025
Listing15 Dec 2025

Quota Reservation Portions

AnchorPortion: 18,34,804 shares
29.73%
QIBPortion: 12,21,729 shares
19.8%
HNIPortion: 9,16,960 shares
14.86%
RetailPortion: 21,39,573 shares
34.67%
Market MakerPortion: 58,036 shares
0.94%

Minimum Application Bracket Matrix

Retail1 lots / 14 shares
₹14,868
sHNI14 lots / 196 shares
₹2,08,152
bHNI68 lots / 952 shares
₹10,11,024

About the Company

Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas including women’s healthcare, cardiology, pain management, urology, and multispecialty segments. As of December 2024, its portfolio includes 67 brands covering women’s health, cardio-diabetic care, pain relief, urology, and multispecialty products such as vitamins, minerals, nutrition, gastrointestinal, and respiratory medications. The company has established a strong pan-India presence with 2,598 medical representatives across 22 states, ensuring deep engagement with healthcare professionals and hospitals. It operates two manufacturing facilities in Gujarat, supporting its production and quality-focused growth strategy in the Indian Pharmaceutical Market.

Company Promoters

Dr. Kirtikumar Laxmidas MehtaNiravkumar Kirtikumar MehtaAnkur Kirtikumar Mehta
Corona Remedies Limited IPO Details | GMP, Allotment & Financials | IPO Trending